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Abstract: This paper describes the properties of nanocrystalline silver products (Acticoat™) and 
their applications and examines available evidence supporting their use in wound management. 
Acticoat utilizes nanotechnology to release nanocrystalline silver crystals. Acticoat releases 30 
times less silver cations than silversulfadiazine cream or 0.5% silver nitrate solution but more 
of the silver released (by Acticoat). Silver-impregnated slow-release dressings release minute 
concentrations of silver which are quickly bound up by the chloride in the wound exudate. 
While extrapolations from in vitro and animal studies are cautious, evidence from these studies 
suggests Acticoat is: effective against most common strains of wound pathogens; can be used 
as a protective covering over skin grafts; has a broader antibiotic spectrum activity; and is 
toxic to keratinocytes and fibroblasts. Animal studies suggest a role for nanocrystalline silver 
in altering wound inflammatory events and facilitation of the early phase of wound healing. 
Quality human clinical trials into nanocrystalline silver are few. However, evidence suggests 
using Acticoat in wound management is cost effective, reduces wound infection, decreases the 
frequency of dressing changes and pain levels, decreases matrix metalloproteinase activity, 
wound exudate and bioburden levels, and promotes wound healing in chronic wounds. Although 
there is no in vivo evidence to suggest nanocrystalline silver is toxic to human keratinocytes 
and fibroblasts, there is in vitro evidence to suggest so; thus these dressings should be used 
cautiously over epithelializing and proliferating wounds. Future clinical research, preferably 
randomized controlled trials into nanocrystalline silver technology, may provide clinicians a 
better understanding of its applications in wound management.
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Introduction
Silver has been used as an antimicrobial since the 1800s. But since the discovery of 
systemic antibiotics in the early 20th century, the use of silver has declined. In the last 
two decades interest in silver for wound treatment resurged. The purpose of this paper is 
two-fold: to describe the properties of recently introduced nanocrystalline silver products 
and their applications in wound care; and to examine available evidence to support the 
use of nanocrystalline in wound care. 
History of silver
Since ancient times silver was used for disinfecting stored water and liquids. The ancient 
Greeks and early Americans used silver coins for this purpose (Fong 2005). Historical 
review reveals silver being used to treat maladies. Prior to the 1800s, silver was used for 
treating epilepsy, venereal infections, acne, and leg ulcers. Silver foil applied to surgical 
wounds were known to improve wound healing and reduce post operative infections, and 
silver pencils were used to remove warts and to debride ulcers (Demling and DeSanti 
2001; Dunn and Edwards-Jones 2004; Fong 2005).
In the late 19th century, 1% silver nitrate solution was instilled into conjuntiva sacs to 
reduce post-partum eye infections. In the late 1960s Moyer and Monafo introduced silver international Journal of Nanomedicine 2006:1(4) 442
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nitrate 0.5% solution for burn wound treatment (Demling and 
DeSanti 2001; Dunn and Edwards-Jones 2004; Fong 2005). 
However, silver nitrate dressings are labour intensive as they 
needed to be applied several times a day or re-moistened 
2 hourly. The potency of silver as an antimicrobial was 
found to be related to the amount and rate of free silver 
released onto the woundbed (Lansdown 2002). In the late 
1960s, Fox introduced silversulfadiazine cream for burn 
wound management. This dramatically revolutionized the 
management of burn wounds by reducing the incidence 
of burn wound infections. Silversulfadiazine cream has a 
relatively short action, its penetration of the burn eschar 
is poor and it forms a pseudo-eschar. Both silver nitrate 
dressings and silversulfadiazine cream require a high 
frequency of dressing changes.
Action of silver 
Silver has antiseptic, antimicrobial, anti-inflammatory 
properties and is a broad spectrum antibiotic (Hoffman 1984; 
Klasen 2000; Demling and DeSanti 2001; Lansdown 2002; 
Dunn and Edwards-Jones 2004; Orvington 2004; Fong 2005). 
Silver is biologically active when it is in soluble form ie, as 
Ag+ or Ag0 clusters. Ag+ is the ionic form present in silver 
nitrate, silversulfadiazine, or other ionic silver compounds. 
Ag0 is the uncharged form of metallic silver present in 
nanocrystalline silver (Dunn 2004). Free silver cations 
have a potent antimicrobial effect which destroys micro-
organisms immediately by blocking the cellular respiration 
and disrupting the function of bacterial cell membranes. This 
occurs when silver cations bind to tissue proteins, causing 
structural changes in the bacterial cell membranes which in 
turn cause cell death. Silver cations also bind and denature 
the bacterial DNA and RNA, thus inhibiting cell replication 
(Tredget et al 1998; Wright and Lam 1998; Yin et al 1999; 
Demling and DeSanti 2001; Lansdown 2002; Thomas 2003a, 
b; Dunn and Edwards-Jones 2004).
Properties and action of 
nanocrystalline silver
There are three types of nanocrystalline wound products: 
ActicoatTM, Acticoat 7, and Acticoat AbsorbentTM. Acticoat 
(ActicoatTM and Acticoat 7) are three or five layered dressing 
constructs of a silver mesh containing silver nanocrystals 
applied to either side of a rayon/polyester core. Nanocrystalline 
silver utilizes nanotechnology to release clusters of extremely 
small and highly reactive silver particles (Smith and Nephew 
2003). The smaller the particles of silver, the greater the wound 
surface area that will be in contact with silver, thus increasing 
bioactivity and silver solubility. Acticoat is made by a process 
called physical vapour deposition. Argon gas is introduced 
into a vacuum chamber acting as an anode. When an electric 
current is passed into the chamber, the argon ions knock out 
the silver atoms travelling towards the substrate to be coated, 
depositing and developing nanocrystals each measuring 15 
nanometres across and are between 30 and 50 atoms. These 
changes to the lattice structure of the crystal result in a high 
energy, meta-stable form of elemental silver (Dunn 2004). 
Acticoat when moistened with sterile water and placed 
on the wound releases clusters of highly reactive silver 
cations up to 100 parts per million, causing electron transport, 
inactivation of bacterial cell DNA, cell membrane damage 
and binding of insoluble complexes in micro-organisms 
(Deitch et al 1987; Orvington 2001; Heggers et al 2002; 
Lansdown 2002; Dunn 2004). Acticoat releases 30 times less 
silver cations than other forms of silver such as 0.5% silver 
nitrate or silversulfadiazine. However, more of the silver 
released is effective and release is sustained (Dunn 2004). 
If re-moistened, Acticoat produces a controlled release of 
clusters of silver cations onto the wound, for up to 3 days (if 
using ActicoatTM) or 7 days (if using Acticoat 7). Research 
has demonstrated that sustained-release silver products 
have a bactericidal action providing effective management 
of odor and exudate, thus reducing the risk for colonization 
and preventing infection (Deitch et al 1987; Orvington 2001; 
Heggers et al 2002; Lansdown 2002; Smith and Nephew   
2003).
Moistening Acticoat has a two-fold benefit: it unleashes 
the antimicrobial power of nanocrystalline silver and assists 
in maintaining a moist environment to promote wound 
healing (Smith and Nephew 2003).
Acticoat AbsorbentTM is an alginate dressing impregnated 
with nanocrystalline silver crystals. It has an absorbent 
property when in contact with wound exudate and forms a 
gel and releases nanocrystalline silver cations onto the wound 
bed. Its antibacterial action is similar to that of ActicoatTM 
(Smith and Nephew 2004).
Wound environment
Controlling micro-organisms within a wound environment 
promotes wound healing. Micro-organisms, ie, bacteria or 
fungi are found in chronic wounds and if present in an acute 
wound can rapidly contaminate and infect, seriously impeding 
wound healing. High levels of bacteria, multi-resistant 
organisms, and bacterial biofilms can impact on the wound-international Journal of Nanomedicine 2006:1(4) 443
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healing process especially in chronic wounds (Templeton 
2005). Bacteria delay wound healing by competing with 
host cells for nutrients and oxygen, their waste products are 
also toxic to host cells. Bacterial wound infection causes 
raised blood cytokines, raised matrix metalloproteinase, and 
decreased growth factors which can have adverse effects on 
wound healing. Local wound infection causes tissue death, 
increase in wound size, wound hypoxia, and vessels occlusion 
which all further delay the wound healing process (Woodward 
2005).
Biofilms are complex communities of bacteria found on 
wound surfaces. They are embedded in a polysaccharide 
matrix and a biofilm functions as one organism in its own 
environment (Templeton 2005; Woodward 2005). A bacterial 
biofilm can have up to 1000 times more resistance to 
conventional antibiotics. Biofilms are prevalent in critically 
colonized wounds which can progress to wound infection 
(Templeton 2005; Woodward 2005). 
A wound bioburden is when bacterial cells produce and 
secrete a variety of enzymes and toxins onto the wound. A 
bacterial population size of 105 colony forming units (cfu)/g 
or cm2 indicates an infected wound and 104 cfu/g or cm2 in 
complex wounds (White 2002). This bacterial load can be 
reduced by the removal of non-viable tissue with debridement 
or by using an antimicrobial dressing such as a sustained 
released silver dressing. In recent years, sustained released 
silver dressings has increasingly been used to treat both 
chronic and acute wounds in an effort to provide a more 
conducive wound healing environment by decreasing the 
wound bioburden level (Wright et al 2003).
Chronic wounds
Wounds that are slow or interrupted in their progress through 
the stages of wound healing are referred as chronic wounds 
(Wright et al 2002; Templeton 2005). They differ from acute 
wounds which heal in a timely and orderly sequential manner. 
Signs of chronic wounds are: presence of necrotic or non-
viable tissue, lack of healthy granulations, recurrent wound 
breakdown, increasing wound size, and a stasis in wound 
improvement. The chronic wound environment has molecular 
and biochemical imbalance. There are elevated levels of matrix 
metalloproteinase and inflammatory cytokines, decreased 
levels of metalloproteinase tissue inhibitors, and growth 
factors in the chronic wound environment (Templeton 2005; 
Wright et al 2003). One of the major factors to delayed wound 
healing is prolonged inflammatory response within the wound 
environment which results in tissue destruction. A high 
level of wound bioburden will also prolong inflammatory 
processes within the wound. Poorly controlled diabetes, 
avascularity, rheumatoid conditions, heart failure, smoking, 
poor nutrition, or continued pressure on the wound are some 
host factors which may impact on and delay wound healing 
causing an acute wound to become a chronic wound (Wright 
et al 2002; Templeton 2005).
Burn wounds and sepsis
Burn wounds are highly susceptible to infection due to the 
impairment of skin integrity and reduction in cell mediated 
immunity (Ayton 1985; Miller 1998; Tredget et al 1998; 
Heggers et al 2002; Fong 2005; Fong et al 2005). Once 
skin integrity is breached, wound colonization and bacterial 
invasion occur. Infection or sepsis is present in a burn wound 
when deposition and multiplication of bacteria in the tissue is 
associated with host reaction or invasion of nearby tissue and 
a bacterial count of 105 cfu/g of tissue (Ayton 1985; Heggers 
et al 1998; White 2002; Fong 2005; Fong et al 2005). Burn 
injury results in tissue destruction and the presence of 
avascular burn eschar provides an environment for infection 
that can progress to septicemia (Kumar et al 1999; Demling 
and DeSanti 2001). Infection is exacerbated by immuno-
suppression often associated with the burn injury (Cook 
1998; Fong 2005). The rate of infection depends on the 
extent of the burn injury, general wound care and various 
host factors such as nutritional status, age, immune status, 
and co-morbidity conditions. The emergence of methicillin 
resistant Staphylococcus aureus (MRSA) and mMulti-
resistant Pseudomonas aeruginosa concerns clinicians, as 
the control of burn wound sepsis is vital to the survival of 
the patient (Cook 1998; Kumar et al 1999; Yin et al 1999; 
Heggers et al 2002; Fong 2005). Burn wound infection 
remains as the main cause of morbidity and mortality for 
patients with burn injuries. 
Evidence to support best practices 
in wound management
Research should be available to direct clinicians towards 
best practice. The efficacy, cost benefits and justification for 
using new technology such as nanocrystalline silver products 
should be thoroughly evaluated and tested prior to changes 
in practice. Randomized controlled trials are the highest level 
of evidence and their findings should be used to influence 
the decision making process in the selection of appropriate 
wound products and to support any changes in practice. The 
body of research falls into three categories: pre-clinical or international Journal of Nanomedicine 2006:1(4) 444
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in vitro studies, animal studies, and human clinical trials   
(Woodward 2005). 
in vitro evidence into nanocrystalline silver
In vitro studies are often the first steps to validate the efficacy 
of a wound product. Extrapolation of in vitro findings to 
the human environment must be cautious as laboratory test 
conditions are significantly different from the human wound 
environment (Woodward 2005). 
Wright et al in 1998 compared 3 types of topical silver 
applications: silver nitrate solution, silver sulfadiazine cream, 
and ActicoatTM against a control dressing to determine their 
bactericidal efficacies against 11 clinical isolates of antibiotic 
resistant organisms. The organisms were inoculated onto each 
of the dressing, incubated for 30 minutes then washed with 
a recovery solution which then was cultured for organism 
survival rate. All the trial dressings demonstrated an ability 
to reduce the number of viable bacteria. The nanocrystalline 
dressing was the most efficacious and silver nitrate solution 
the least efficacious. The researchers concluded silver was 
efficacious for killing the antibiotic resistant bacteria strains 
that were tested. ActicoatTM was found to be particularly rapid 
at killing the tested bacteria and effective against a broader 
range of bacteria than the other trial dressings (Wright et 
al 1998).
Yin et al in 1999 compared the antibacterial activity of 
ActicoatTM with silver nitrate solution, silver sulfadiazine 
cream, and mafenide acetate against 5 clinically relevant 
bacteria. ActicoatTM was found to be more rapid in the 
delivery of silver cations and achieved a faster reduction 
of bacteria than the other experimental dressings. The 
mechanism of killing is similar in all forms of silver products 
but ActicoatTM killed faster as the bacteria take up silver 
faster in ActicoatTM samples (Yin et al 1999). Wright et al in 
1999 examined the in vitro fungicidal efficacy of a variety of 
topical agents. Fungal isolates were inoculated onto mafenide 
acetate, silver nitrate, silversulfadiazine cream and ActicoatTM 
dressings, then incubated, and the fungi survival rate was 
evaluated. All the antimicrobial dressings were found to be 
effective against fungi. The nanocrystalline dressing provided 
the fastest kill rate and the broadest spectrum activity against 
fungi (Wright et al 1999).
Thomas et al in 2003 compared 4 silver containing 
dressings: ActicoatTM, ActisorbTM, Silver220TM, AvanceTM, 
and Contreet-HTM in another in vitro experiment. They 
showed that antimicrobial activity was more rapid with 
nanocrystalline silver against Gram positive and Gram 
negative bacteria and a yeast. The silver foam (Contreet-HTM) 
product was shown not to release silver ions but will absorb 
the microbes (Thomas 2003a).
Another experiment was conducted by the same 
researchers in the same year using a larger variety of silver 
products. Again they demonstrated that silver products varied 
in their antimicrobial activity – some had little or no effect 
on the microbes tested. Acticoat 7 killed 99.9% methicillin 
resistant Staphylococcus aureus at all the intervals the 
samples were read (Thomas 2003b).
Wright et al in the same year questioned if antimicrobial 
efficacy alone is sufficient to justify their use. ActicoatTM 
was compared with a gauze dressing impregnated with 
hexamethylene biguanide against clinical innoculates of 
bacteria. Both dressings were demonstrated to have potent 
in vitro antibacterial effect. Acticoat activity diffused into the 
surrounding environment, whereas the activity of the gauze 
dressing with hexamethylene biguanide was confined within 
its borders (Wright et al 2003).
Holder et al in 2003 tested ActicoatTM and N TerfaceTM   
with filter paper as control dressing in 3 in vitro assays. 
ActicoatTM served as an impenetrable barrier for all 
organisms tested. They concluded that ActicoatTM was 
suitable for protection against environmental organisms 
for use with skin grafts on excised burns (Holder et al 
2003). Fraser in 2003 conducted an in vitro study to test the 
efficacy of silversulfadiazine cream and ActicoatTM against 
8 common burn wound pathogens. They demonstrated that 
silversulfadiazine cream was more efficacious against killing 
all tested organisms than ActicoatTM (Fraser 2003).
The same researcher conducted another in vitro study 
in the following year to determine the cytotoxicity of 
silversulfadiazine cream and ActicoatTM applied to the 
centres of culture plates seeded with keratinocytes, then 
incubated for 7 hours and the culture medium plates were 
read for keratinocyte survival rates. Silversulfadiazine 
cream was found to be more cytotoxic to keratinocytes than 
ActicoatTM (Fraser 2004). Poon et al in 2004 examined the 
effects of silver on keratinocytes and fibroblasts in another 
in vitro study. Silver nitrate solution and ActicoatTM were 
the two experimental dressings. They demonstrated that 
silver was toxic to skin cells, fibroblasts and keratinocytes as 
well as to bacteria. They cautioned the use of silver products 
where rapidly proliferating keratinocytes are exposed such 
as in donor sites, superficial partial thickness wounds and 
undifferentiated cultured keratinocyte applications (Poon and   
Burd 2004).international Journal of Nanomedicine 2006:1(4) 445
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In summary, the literature indicates there is in vitro 
evidence to support the efficacy of using nanocrystalline 
silver for wound management. Nanocrystalline silver as an 
antimicrobial is effective against most common strains of 
bacteria, including multi-resistant strains and fungi spores. In 
vitro evidence indicates that nanocrystalline silver achieved 
the best killing rates for numerous mico-organisms, can be 
used as a protective covering over skin grafts, has a broader 
antibiotic spectrum activity, and is toxic to keratinocytes and 
fibroblasts.
evidence from animal studies into  
nanocrystalline silver
Wright et al in 2002 examined early healing events and the 
efficacy of nanocrystalline silver on the levels of matrix 
metalloproteinase, cell apoptosis and healing in a porcine 
model of contaminated wounds. Full thickness wounds were 
created on the backs of pigs, contaminated with experimental 
inoculum of Pseudomonas, Fusobacterium species, and 
coagulative negative strains of Staphlyococci, and covered 
with dressing products with or without nanocrystalline 
silver. They found the nanocrystalline silver product 
promoted rapid wound healing in the first few days post 
injury and the proteolytic environment of wounds treated 
with nanocrystalline silver was changed by the reduction 
of levels of matrix metalloproteinase. In chronic ulcers, 
matrix metalloproteinase levels have been shown to be pro-
inflammatory and at abnormally high levels compared with 
acute wounds. This may contribute to the non-healing nature 
of these wounds. Cellular apoptosis occurred at a higher rate 
in non-nanocrystalline silver-treated wounds. This suggested 
nanocrystalline silver has a role in altering the inflammatory 
events in wounds and facilitate the early phase of wound 
healing (Wright et al 2002).
The same authors in 2003 questioned the antimicrobial 
efficacy of new silver dressings in reducing the bacterial bioburden 
in acute and chronic wounds. They compared nanocrystalline 
silver and a gauze dressing impregnated with polyhexamethylene 
biguanide in an animal model of wound healing. They found the 
wound dressed with nanocrystalline silver product progressed 
to full granulation faster and had lower bacterial bioburden 
levels than the wound dressed with non-nanocrystalline silver 
product. The authors concluded that being an antimicrobial is not 
sufficient, the dressing needed to promote wound healing. The 
gauze dressing with polyhexamethlyene biguanide prolonged 
inflammatory response and had a negative effect on wound 
healing (Wright et al 2003).
The therapeutic efficacy of 3 silver dressings in an infected 
animal model were examined by Heggers et al in 2005. 
ActicoatTM, SilverlonTM, SilvasorbTM, and a control dressing 
were applied to 4 groups of rats. The rats received contact 
burns and were surgically infected with Pseudomonas 
aeruginosa and Staphylococcus aureus on day 3 post burns. 
The dressings were evaluated and quantitatively assessed 
in 10 days. ActicoatTM and SilvasorbTM treated wounds had 
significantly lower bacterial counts than the SilverlonTM 
treated wounds. They demonstrated that weekly dressing 
changes were feasible when treating wounds with ActicoatTM 
or SilvasorbTM (Heggers et al 2005).
Ulkur et al in 2004 compared ActicoatTM, chlorhexidine 
acetate, and silversulfadiazine cream as topical antibacterial in 
pseudomonas contaminated full thickness burn wounds in rats. 
All the experimental dressings were effective; however they 
concluded that ActicoatTM may be the dressing of choice due to 
the limited frequency of dressing changes (Ulkur et al 2005a).
The same authors in the following year compared 
ActicoatTM, chlorhexidine acetate 0.5%, and fusidic acid 
2% for topical antibacterial effect in methicillin resistant 
Staphylococci-contaminated full thickness rat burn wounds. 
Thirty-two male Wistar rats received full thickness dorsal 
scald burns to 15% of their body surface area, resuscitated 
and then infected with the experimental micro-organism, 
methicillin resistant Staphylococcus aureus, and placed in 
separate cages to recover. After 24 hours they were randomly 
assigned to topical applications of the experimental dressings 
and one group with no dressings applied to act as control. All 
animals were killed on day 7 and measurements of weight 
obtained. Cultures were obtained from punch biopsies of 
the eschars and tested for the test microbe. They found that 
fusidic acid was the most effective agent in treating methicillin 
resistant Staphylococcus aureus-contaminated burn wounds, 
but ActicoatTM was the preferred treatment due to its ability to 
limit the frequency of dressing changes (Ulkur et al 2005b).
Supp et al in 2005 evaluated the cytoxicity and 
antimicrobial activity of ActicoatTM for management of 
microbial contamination in cultured skin substitutes grafted 
to anthymic mice. The cytoxocity of ActicoatTM was assessed 
after 1, 2, 3, and 4 weeks of grafting with cultured skin 
substitutes. They found contaminated wounds treated with 
ActicoatTM healed similarly to control treatments. These 
results suggested that ActicoatTM could be used as a protective 
dressing to reduce environmental contamination of cultured 
skin substitutes to control organisms present in the wound 
(Supp et al 2005).international Journal of Nanomedicine 2006:1(4) 446
Fong and wood
In summary, there is a lack of animal studies on 
nanocrystalline silver, but the available literature reviewed 
suggested that nanocrystalline silver has a role in altering the 
inflammatory events in wounds and also facilitate the early 
phase of wound healing. There is evidence to suggest that 
ActicoatTM is an effective antimicrobial and is the dressing of 
choice in several cases as it limits the frequency of dressing 
changes. ActicoatTM may be suitable as a protection for 
contamination on cultured skin substitutes used for wound 
closure. Animals and humans differ in structure and function. 
Therefore extrapolations of findings from animal models to 
the human environment must be done with caution. 
evidence from human studies into 
nanocrystalline silver
There is a lack of high quality designed research such as 
randomized control trials in human studies into nanocrystalline 
silver dressings. However a search of the literature revealed 
many human comparative studies, case series, and individual 
reports of the applications of nanocrystalline silver in wound 
management. 
In an earlier study in 1998 Tredget conducted a matched 
paired randomized study to evaluate the efficacy and safety 
of ActicoatTM for burn wound treatment. Thirty patients with 
symmetrical burns were randomly assigned to be dressed with 
ActicoatTM or silver nitrate solution dressings. They found that 
the ActicoatTM-treated patients had less pain levels initially 
but the pain levels were comparable with that of the silver 
nitrate group of patients after 2 hours. They also found that 
the frequency of dressing changes and incidence of wound 
sepsis were less in the ActicoatTM-treated group (Tredget   
et al 1998).
Voight presented case presentations of 6 patients with 
venous ulcers treated with ActicoatTM. They reported wound 
healing in these patients, one patient with a 5 month old ulcer 
was healed with ActicoatTM in 194 days and another with a 
5-week-old ulcer which healed in 27 days. In another case 
series, Voight demonstrated the effects of ActicoatTM on 4 
patients with debicutus ulcers, one with a 24-month-old ulcer 
healed in 27 days and another 2-week-old ulcer healed in 
14 days with ActicoatTM. They demonstrated a reduction in 
exudate fluid volumes in all cases treated with ActicoatTM. The 
same authors conducted a multi-centered (41 centers) survey 
for the use of ActicoatTM dressing. They reported that 61% of 
the centres surveyed used ActicoatTM and up to 52% of these 
used ActicoatTM as a cover for Integra, a dermal regeneration 
template for full thickness burns reconstruction. They also 
reported that 4.8% of those surveyed used ActicoatTM as their 
principal dressing. They concluded that ActicoatTM is cost 
effective, improved wound healing and able to be applied to 
all types of wounds (Voight and Paul 2001).
Innes in 2001 investigated the use of ActicoatTM and 
Allevyn foam on donor sites in a prospective controlled 
matched pair study on 15 patients with bilateral donor sites. 
They found that donors treated with Allevyn foam were 
more than 90% re-epitheliased at a mean 9.1 days, whereas 
the ActicoatTM-treated donor sites were more than 90% 
re-epitheliased at 14.5 days. They concluded Allevyn was 
significantly better than ActicoatTM for treating donor sites 
and the ActicoatTM-treated donor sites had worse scars at 2 
weeks than Allevyn-treated donors but showed no difference 
at 3 months (Innes et al 2001).
The role of silver in wound healing was examined in 
a single center, open-label, unblinded pilot study of 11 
extended-care facility outpatients or residents with chronic 
wounds of mixed etiology by Kirshner et al in 2002. All 
wounds had a history of at least 3 months and had no 
decrease in wound size in the 3 weeks preceding the study. 
The patients were all treated with ActicoatTM and had their 
dressings changed daily in the first week and on alternate 
days therafter. All used dressings were reserved for analyses 
and fluid collection. Eight patients completed the study, the 
authors found a decrease in matrix metalloproteinase activity 
in the first 2 days of treatment. This suggested that once 
matrix metalloproteinase activity is altered it can remain so 
with the continued use of the nanocrystalline silver dressing 
(Kirshner 2002).
Demling and DeSanti in 2002 examined the effects of 
ActicoatTM and XeroformTM as dressings over meshed skin 
grafts. Twenty patients, each having 2 areas of meshed skin 
grafts were treated with ActicoatTM in one and XeroformTM 
with 0.01% neomycin and polymyxin on the other wound. 
Wounds were evaluated every 3 days and wound swabs 
obtained. They found that ActicoatTM greatly increased the 
rate of wound closure than the standard XeroformTM dressings 
(Demling and DeSanti 2002).
Dunn in 2004 presented reports from the 2003 European 
Burns Association meeting of success with the use of 
ActicoatTM on burn patients by several clinicians across 
Europe. ActicoatTM dressings were applied to children with 
partial to full thickness burns. Besides the antimicrobial 
effects ActicoatTM-treated wounds generally improved and 
healed naturally or in conjunction with surgical interventions. 
There were reports of improved pain levels, reduction in the international Journal of Nanomedicine 2006:1(4) 447
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frequency of dressing changes, wound exudate and number 
of surgical procedures (Dunn 2004).
Lansdown in 2005 conducted a sequential microbiology 
examination of wound swabs from 7 patients with chronic 
wounds and sampling wound exudates and wound scale. 
They compared Acticoat 7, Actisorb Silver, Contreet-HTM, 
AquacelAg, and FlamazineTM. They found in all cases the 
bacterial bioburden to be reduced but not completely 
eliminated (Lansdown et al 2005).
In a randomized control study Varas et al in 2005 
examined 14 burn patients pain levels after dressing changes. 
Patients had 2 areas of burns and were randomly assigned 
to ActicoatTM or silversulfadiazine cream dressings. Patients 
were used as their own control. They found that ActicoatTM-
treated wounds were less painful than the silversulfadiazine 
cream treated wounds (Varas et al 2005).
Fong et al in 2005 conducted 2 comparative patient 
care audits and a historically controlled matched paired 
comparision to examine the use of ActicoatTM in decreasing 
the incidence of early burn wound infection and its cost 
effectiveness. Patient care audits demonstrated that the 
ActicoatTM treated group (treatment group) had a significantly 
lower infection rate (5.2%) than the silversulfadiazine cream 
treated group(control group) with 55% infection rate. They 
demonstrated cost savings for the matched paired sample 
(4 pairs of patients) comparison of the two treatments, the 
ActicoatTM treated sample saved AU$7612 per patient. They 
also reported lower pain levels in the ActicoatTM patients 
and subjective observations made by staff who looked 
after both the ActicoatTM and silversulfadiazine cream 
groups of patients suggested that the ActicoatTM group of 
patients had higher levels of feelings of wellbeing due to 
lower pain levels and less frequent dressing changes (Fong   
et al 2005). Sibbald in 2005 in an open pilot study of prolonged 
release nanocrystalline silver dressing (Acticoat 7): reduction 
of bacterial burden treatment in the treatment of chronic 
venous leg ulcers reported a case series of 15 patients. Patients 
were treated with Acticoat 7 under a four layer of Profore 
compression bandages for a 12-week period or until healed. 
Results demonstrated an ionized silver dressing with prolonged 
release of nanocrystalline silver (Acticoat 7) can decrease 
bacterial burden and accelerate wound healing in venous ulcers 
not healing at the expected rate (Sibbald et al 2005a). 
The same authors reported in the same study the anti-
inflammatory activity of prolonged released nanocrystalline 
silver (Acticoat 7) in the treatment of chronic venous leg 
ulcers, nanocrystalline silver dressing has an antibacterial and 
permissive but selective anti-inflammatory action in reducing 
the size of venous ulcers (Sibbald et al 2005b).
Rustogi et al in 2005 evaluated the safety and efficacy 
of ActicoatTM use in primary burn injuries and other skin 
injuries in premature neonates. An audit of eight premature 
neonates who sustained burn injuries and other cutaneous 
injuries from various agents were treated with ActicoatTM. 
The percentage of skin loss was from 1 to 30%. The wounds 
were assessed for infection and blood cultures were taken to 
exclude sepsis.
Four neonates went on to heal within 28 days, the 
other four neonates died, secondary to problems from 
extreme prematurity. They reported no wound infections 
or positive blood cultures in the trial period and concluded 
that ActicoatTM is suitable for use as a dressing for neonates 
(Rustogi et al 2005).
In summary, the literature review of nanocrystalline 
silver used on humans for wound management suggested 
nanocrystaline silver is: cost effective, reduces burn wound 
incidence, decreases pain levels during dressing changes, 
decreases the frequency of dressing changes, decreases 
the matrix metalloproteinase activity, reduces the wound 
exudate and bioburden levels, and promotes wound healing 
in chronic wounds. There is no in vivo evidence to suggest 
that nanocrystalline silver is toxic to skin cells such as 
keratinocytes and fibroblasts. 
Conclusion
Research indicates nanocrystalline silver dressing is an 
effective antimicrobial for treating wounds especially burns 
and chronic wounds. ActicoatTM reduces the inflammatory 
processes and promotes wound healing and is less toxic than 
other forms of silver dressings due to the prolonged release 
of silver onto the wound. There has been no in vivo reports 
of toxicity of nanocrystalline silver on keratinocytes or 
fibroblasts, but there is in vitro evidence to suggest so. Thus, 
clinicians should be cautious in the use of nanocrystalline 
dressings over epitheliazing and proliferating wounds. 
Evidence from clinical trials, various case presentations, and 
reports suggests that the use of ActicoatTM is cost effective, 
reduces pain levels, and has a longer wear time, thus limiting 
the frequency of dressing changes. There has been no reports 
of resistance to Acticoat dressings; however, clinicians should 
use Acticoat dressings judiciously, applying the dressings to 
the appropriate wounds and ceasing their use appropriately 
to prevent the development of bacterial resistance. Clinicians 
are increasing in their use of nanocrystalline silver dressings international Journal of Nanomedicine 2006:1(4) 448
Fong and wood
for wound management either for their antimicrobial or 
anti-inflammatory properties. More quality clinical research 
should be conducted in order to direct clinicians in their 
decision making process in choice of dressings and to provide 
more evidence for best practices in wound management. 
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